Randomized Controlled Trials of the Effects of Decadron on Swallowing, Airway, and Arthrodesis
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Anterior cervical discectomy and fusion with or without decompression is a well-established surgical treatment for spine patients with the appropriate indications. Anterior approach involves some retraction that affect the midline structures of the anterior neck. Irritation and swelling may result, leading to postoperative dysphagia and the less common but critically important occurrence of postoperative airway compromise. Steroids given intraoperatively may reduce the incidence of these adverse outcomes by reducing the degree of swelling within the anterior neck subsequent to local surgical tissue trauma.
The investigators hypothesize that the use of steroids intraoperatively provides a significant benefit to the patient, in terms of reduced incidence of dysphagia and airway compromise.
| Condition | Intervention | Phase |
|---|---|---|
|
Swallowing |
Drug: Decadron Drug: Saline |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | Prospective Randomized Controlled Trail of the Effects of Steroids on Swallowing, Airway and Arthrodesis Related to Myulti-Level Anterior Cervical Reconstruction |
- subjects will demonstrate good bony fusion [ Time Frame: one year ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 200 |
| Study Start Date: | November 2008 |
| Estimated Study Completion Date: | November 2016 |
| Estimated Primary Completion Date: | November 2016 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Decadron
Subject will be given Decadron 0.2mg/kg intraoperatively. This dose will be followed by 4 mg. every 6 hours for the first 24 hours.
|
Drug: Decadron
Decadron will be given at a dose of 0.2 mg/kg intraoperatively, followed by Decadron 4 mg. every 6 hours for 24 hours.
|
|
Placebo Comparator: Saline
subject will be given a blinded dose of placebo saline intraoperatively followed by placebo doses every 6 hours for 24 hours.
|
Drug: Saline
Placebo saline will be given intraoperatively as well as 4 doses every 6 hours for 24 hours.
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 18 years of age or greater
- Cervical spondylosis requiring surgical treatment at 2 or more motion segments
- Ventrally - approachable vertebral levels
Exclusion Criteria:
- Minors (under 18 years old)
- Pregnant women
- Patients currently taking steroids
- Patients requiring surgical treatment at only one segment
- Comatose or incapacitated patients who cannot consent to participate
- Wards of the state
- Persons with an allergy to dexamethasone or related drugs
- Persons employed at Albany Medical Center
Contacts and Locations| Contact: Darryl DiRisio, MD | 518 262-5088 | dirisi@mail.amc.edu |
| Contact: Margaret Czerwinski, BSN, RN | 518 262-0034 | czerwim@mail.amc.edu |
| United States, New York | |
| Albany Medical Center | Recruiting |
| Albany, New York, United States, 12208 | |
More Information
No publications provided
| Responsible Party: | Darryl DiRisio, MD, Albany Medical Center |
| ClinicalTrials.gov Identifier: | NCT01065961 History of Changes |
| Other Study ID Numbers: | D-01 |
| Study First Received: | February 9, 2010 |
| Last Updated: | February 9, 2010 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Albany Medical College:
|
anterior cervical fusion |
swallowing Swallowing after anterior cervical discectomy and fusion Bony fusion rates post anterior cervical discectomy and fusion |
Additional relevant MeSH terms:
|
Dexamethasone acetate Dexamethasone Dexamethasone 21-phosphate BB 1101 Anti-Inflammatory Agents Therapeutic Uses Pharmacologic Actions Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs |
Central Nervous System Agents Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antineoplastic Agents Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 16, 2013